Indian generics dominate global ranking

Drug maker has given the highest ‘Total Shareholder Return (TSR)’ in the past three years, according to a recent study of the major global generic drug manufacturers by The (BCG).

The BCG analysis shows Lupin gave an annualised average TSR of 29.9 per cent, ahead of the 18.4 per cent of Israel-based Teva Pharmaceutical, the world’s largest generics maker. Teva is next on the list.

Another Indian generic maker, Glenmark, occupies third position, with an 18 per cent TSR to its investors.

Of the nine generic that gave good benefits to their shareholders, seven are Indian companies, said the study.
 

INDIA RULES
Total Shareholder Returns (TSR) of generic companies for three years 
Company

TSR (%)

Lupin 29.9
Teva 18.4
Glenmark 18.0
Watson 15.8
Sun Pharma 13.7
Dr Reddy’s 6.2
Cipla 6.2
Jubilant 0.0
Source: BCG global generics report

Sun Pharmaceutical, which is India’s largest drug company in terms of market capitalisation, occupies the fifth position, with a TSR of 13.7 per cent. Dr Reddy’s Laboratories and Cipla, two of the largest domestic drug companies, follow Sun Pharma with 6.2 per cent TSR each.

Sources said BCG’s latest annual study on TSR was based on a unique benchmark, using four main parameters — change in share prices, profit growth, investor expectations and cash flow yield. This was done for the period from August 2006 to July 2009. The study is based on data from Standard and Poor’s Global Vantage and the BCG Value Science Centre, they said.

Apart from Teva, the US-based Watson Pharma is the only overseas generic company that gave good returns, of 15.8 per cent annually, said the study released in September.

“We consume close to 70 per cent of our active pharmaceutical ingredients (API) to create formulations. This backward integration model has not only given us cost leadership, but unbeatable margins and the highest per product revenues, and a distinct well-defined profitability than others globally,” explained Nilesh Gupta, group president and executive director, Lupin.

Lupin also has the distinction of being among the fastest growing top 10 generic makers in two of the largest markets of the world, the US and Japan. Over the past five years, the company has recorded a compounded annual growth rate (CAGR) of 31 per cent in terms of sales and 53 per cent in net profits, respectively. It’s also the fastest growing among the top five Indian drug companies, said company sources.

image
Business Standard
177 22
Business Standard

Indian generics dominate global ranking

P B Jayakumar  |  Mumbai 



Drug maker has given the highest ‘Total Shareholder Return (TSR)’ in the past three years, according to a recent study of the major global generic drug manufacturers by The (BCG).

The BCG analysis shows Lupin gave an annualised average TSR of 29.9 per cent, ahead of the 18.4 per cent of Israel-based Teva Pharmaceutical, the world’s largest generics maker. Teva is next on the list.

Another Indian generic maker, Glenmark, occupies third position, with an 18 per cent TSR to its investors.

Of the nine generic that gave good benefits to their shareholders, seven are Indian companies, said the study.
 

INDIA RULES
Total Shareholder Returns (TSR) of generic companies for three years 
Company

TSR (%)

Lupin 29.9
Teva 18.4
Glenmark 18.0
Watson 15.8
Sun Pharma 13.7
Dr Reddy’s 6.2
Cipla 6.2
Jubilant 0.0
Source: BCG global generics report

Sun Pharmaceutical, which is India’s largest drug company in terms of market capitalisation, occupies the fifth position, with a TSR of 13.7 per cent. Dr Reddy’s Laboratories and Cipla, two of the largest domestic drug companies, follow Sun Pharma with 6.2 per cent TSR each.

Sources said BCG’s latest annual study on TSR was based on a unique benchmark, using four main parameters — change in share prices, profit growth, investor expectations and cash flow yield. This was done for the period from August 2006 to July 2009. The study is based on data from Standard and Poor’s Global Vantage and the BCG Value Science Centre, they said.

Apart from Teva, the US-based Watson Pharma is the only overseas generic company that gave good returns, of 15.8 per cent annually, said the study released in September.

“We consume close to 70 per cent of our active pharmaceutical ingredients (API) to create formulations. This backward integration model has not only given us cost leadership, but unbeatable margins and the highest per product revenues, and a distinct well-defined profitability than others globally,” explained Nilesh Gupta, group president and executive director, Lupin.

Lupin also has the distinction of being among the fastest growing top 10 generic makers in two of the largest markets of the world, the US and Japan. Over the past five years, the company has recorded a compounded annual growth rate (CAGR) of 31 per cent in terms of sales and 53 per cent in net profits, respectively. It’s also the fastest growing among the top five Indian drug companies, said company sources.

RECOMMENDED FOR YOU

Indian generics dominate global ranking

Drug maker Lupin has given the highest ‘Total Shareholder Return (TSR)’ in the past three years, according to a recent study of the major global generic drug manufacturers by The Boston Consulting Group (BCG).

Drug maker has given the highest ‘Total Shareholder Return (TSR)’ in the past three years, according to a recent study of the major global generic drug manufacturers by The (BCG).

The BCG analysis shows Lupin gave an annualised average TSR of 29.9 per cent, ahead of the 18.4 per cent of Israel-based Teva Pharmaceutical, the world’s largest generics maker. Teva is next on the list.

Another Indian generic maker, Glenmark, occupies third position, with an 18 per cent TSR to its investors.

Of the nine generic that gave good benefits to their shareholders, seven are Indian companies, said the study.
 

INDIA RULES
Total Shareholder Returns (TSR) of generic companies for three years 
Company

TSR (%)

Lupin 29.9
Teva 18.4
Glenmark 18.0
Watson 15.8
Sun Pharma 13.7
Dr Reddy’s 6.2
Cipla 6.2
Jubilant 0.0
Source: BCG global generics report

Sun Pharmaceutical, which is India’s largest drug company in terms of market capitalisation, occupies the fifth position, with a TSR of 13.7 per cent. Dr Reddy’s Laboratories and Cipla, two of the largest domestic drug companies, follow Sun Pharma with 6.2 per cent TSR each.

Sources said BCG’s latest annual study on TSR was based on a unique benchmark, using four main parameters — change in share prices, profit growth, investor expectations and cash flow yield. This was done for the period from August 2006 to July 2009. The study is based on data from Standard and Poor’s Global Vantage and the BCG Value Science Centre, they said.

Apart from Teva, the US-based Watson Pharma is the only overseas generic company that gave good returns, of 15.8 per cent annually, said the study released in September.

“We consume close to 70 per cent of our active pharmaceutical ingredients (API) to create formulations. This backward integration model has not only given us cost leadership, but unbeatable margins and the highest per product revenues, and a distinct well-defined profitability than others globally,” explained Nilesh Gupta, group president and executive director, Lupin.

Lupin also has the distinction of being among the fastest growing top 10 generic makers in two of the largest markets of the world, the US and Japan. Over the past five years, the company has recorded a compounded annual growth rate (CAGR) of 31 per cent in terms of sales and 53 per cent in net profits, respectively. It’s also the fastest growing among the top five Indian drug companies, said company sources.

image
Business Standard
177 22
Widgets Magazine

More News

  • Welspun Welspun faces new probe from Bed Bath & Beyond, shares pressured
  • Sun TV profit up by 16% in Q4 Ad revenue growth in FY17 key trigger for Sun TV
Widgets Magazine
Widgets Magazine

Upgrade To Premium Services

Welcome User

Business Standard is happy to inform you of the launch of "Business Standard Premium Services"

As a premium subscriber you get an across device unfettered access to a range of services which include:

  • Access Exclusive content - articles, features & opinion pieces
  • Weekly Industry/Genre specific newsletters - Choose multiple industries/genres
  • Access to 17 plus years of content archives
  • Set Stock price alerts for your portfolio and watch list and get them delivered to your e-mail box
  • End of day news alerts on 5 companies (via email)
  • NEW: Get seamless access to WSJ.com at a great price. No additional sign-up required.
 

Premium Services

In Partnership with

 

Dear Guest,

 

Welcome to the premium services of Business Standard brought to you courtesy FIS.
Kindly visit the Manage my subscription page to discover the benefits of this programme.

Enjoy Reading!
Team Business Standard